Rose Hill's New Clinical Data Published by the Johns Hopkins University

LEARN MORE
CONTACT US

Advancing Biotechnology in the Massachusetts Life Sciences Hub

Rose Hill Life Sciences is a premier Biotechnology Company in Massachusetts, specializing in the clinical research and development of Psilocybe cubensis. We operate at the intersection of rigorous science and therapeutic innovation to serve the Boston biotech community and global researchers.

CONTACT OUR RESEARCH TEAM

RESEARCH PARTNERS

johns-hopkins-university-logo.webp
Psychedelic-Association-of-Canada-logo.webp
university-of-guelph-logo.webp
Canadian-Center-for-Psycodelic-Science-logo.webp
ACS-laboratory-logo.webp
Biocase brasil

ROSE HILL LIFE SCIENCES IN THE MEDIA

vice-logo
hit-consultant-logo.webp
hcp-life-logo.webp
Jamaica-observer-logo.webp
rolling-stone-logo.webp
Psychedelic Medicine Podcast
inside precision medicine

Who We Are

Leading Innovation in Psychedelic Medicine

Situated at the intersection of biotechnology and mental health, Rose Hill Life Sciences is dedicated to validating psilocybin as a medical treatment. We operate as a critical infrastructure partner for the Massachusetts biotech community, supplying the data and standardized materials needed for FDA-compliant studies.

By collaborating with Principal Investigators and research hospitals, we facilitate rigorous clinical trials aimed at Stroke recovery, PTSD, and Autism Spectrum Disorder (ASD).

SEE WHAT WE DO

Who We Are

Rose Hill Life Sciences is committed to psychedelics as a way to improve all areas of healthcare.

Psychedelics are at the forefront of transforming healthcare and At Rose Hill Life Sciences, we are on a mission to unlock the therapeutic potential of psychedelics, such as psilocybin, to address a wide range of health challenges.

By collaborating with leading scientists, clinicians, and institutions, we conduct rigorous clinical trials and cutting-edge studies to develop safe, effective treatments.

Committed to scientific excellence, we share our discoveries with the global medical and research communities to advance health equity and improve lives worldwide.

WHAT WE DO?

What We Do

Pioneering the Future of Psychedelic Medicine in New England.

Clinical Research Partnerships

We support the drug development pipeline by partnering with world-class institutions, including Johns Hopkins University and the University of Guelph. We supply research-grade biomass to sponsor-led studies, ensuring Massachusetts researchers have access to standardized inputs that meet Institutional Review Board (IRB) standards.

FIND OUT MORE

Chemical Analytics & Standardization

In the rigorous landscape of biotech research, consistency is everything. Our team uses data-backed analysis to map the full alkaloid profile of our strains. We ensure that every gram of biomass supplied to your lab is chemically defined and reproducible, essential for regulatory approval.

FIND OUT MORE

IP & Novel Formulations

Our R&D initiatives target novel formulations for neurodegenerative conditions. We are actively investigating the role of specific tryptamines in reopening “critical periods” of brain plasticity, a key area of focus for Boston’s neurology research community treating Traumatic Brain Injury (TBI).

FIND OUT MORE

Global Supply Chain

We operate a “seed-to-sale” model where legal international cultivation supports domestic research. We manage the complex logistics of importing research-grade psilocybin to Massachusetts, handling regulatory compliance so your team can focus on the data.

FIND OUT MORE

Meet Our Team

Our leadership combines expertise in molecular biology, regulatory affairs, and international logistics. We are united by a data-centric approach to legitimizing psychedelic medicines within the medical establishment.

Charles Lazarus

Chief Executive Officer

Jama Pitman

Regulatory Strategy

Burton J. Tabaac

MD, FAHA | Clinical Development

Rotem Petranker, PhD

Psychology Psychedelic Researcher

Domenic Suppa

Chief Operating Officer

Kevin Bourke

Chief Commercial Officer

Adam Goodman

Advisor

MORE ABOUT OUR TEAM

Latest News

Top Psilocybin Companies to Invest in 2026

February 17, 2026

Top Psilocybin Stocks to Invest In for Beginners

February 17, 2026

The Beginner’s Guide to Psilocybin ETFs to Invest In

February 17, 2026

Psilocybin Therapy Why Results Differ Between People in Research Studies

February 10, 2026
MOre ON OUR BLOG

Partner with our Massachusetts Research Team

Have questions about our current psychedelic research or upcoming studies? Share your details and our Massachusetts team will get back to you.

Frequently Asked Questions

What is Rose Hill Life Sciences’ focus?

We are a biotechnology company focused on IP creation and clinical supply. We serve the Massachusetts life sciences sector by providing research-grade psilocybin to universities and private labs.

We operate a hybrid model: our research partnerships are centered in North America (specifically MA and Canada), while our cultivation facilities operate in Jamaica to ensure federal compliance and export capability.

No. We do not sell consumer products in the United States. We strictly supply biomass to licensed researchers and institutions.

GET IN TOUCH
Dedicated to Psilocybin Research, Development, and Clinical Application
Get In Touch Now

About Us

Clinicals

Get to Know Us

X-twitter Facebook Linkedin-in Instagram
  • Privacy Policy
  • Copyright © 2015 - 2025 Rose Hill Life Sciences All Rights Reserved.
CONTACT US

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.

Instagram Linkedin-in

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Linkedin-in

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Linkedin-in

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.